Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer. Patients with high-risk muscle-invasive urothelial ...
Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...
As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022 WHO classification of urinary tract tumors includes a list of less common subtypes (formerly known as variants) for ...
Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...
The National Institute for Health and Care Excellence (NICE) has recommended erdafitinib (Balversa, Johnson & Johnson) as a treatment option for adults with unresectable or metastatic urothelial ...
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine. While cisplatin ...
Evidence for plasma-based circulating tumor DNA (ctDNA) as a prognostic and predictive marker in urothelial carcinoma is helping to transform the diagnostic and management landscape. Joaquin Bellmunt, ...
They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results